Meeting Overview - The second session of the Supervisory Board's sixteenth meeting was held on June 4, 2025, in Shanghai, with all three supervisors present, confirming the legality and validity of the meeting [1]. Resolutions Passed - The Supervisory Board unanimously approved the proposal to revise the "Director and Supervisor Remuneration Management System," which will be submitted to the shareholders' meeting for approval [2]. - The revised profit distribution plan for 2024 was deemed beneficial for the company's sustainable development and aligned with shareholder interests, ensuring no harm to minority shareholders [2][3].

证券代码：603122 证券简称：合富中国 公告编号：临 2025-023 合富（中国）医疗科技股份有限公司 关于召开2024年年度股东大会的通知 本公司董事会及及除独立董事Stanley Yi Chang先生以外的董事保证本公告 内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准 确性和完整性承担法律责任。 重要内容提示： ? 股东大会召开日期：2025年6月25日 ? 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票系 统 一、 召开会议的基本情况 (一) 股东大会类型和届次 (二) 股东大会召集人：董事会 (三) 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相 结合的方式 (四) 现场会议召开的日期、时间和地点 召开的日期时间：2025 年 6 月 25 日 14 点 30 分 召开地点：上海市徐汇区虹漕路 456 号光启大楼 20 楼会议室 无。 二、 会议审议事项 本次股东大会审议议案及投票股东类型 (五) 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 6 月 25 日 至20 ...

独立董事候选人声明与承诺 本 人 翁文能，已充分了解并同意由提名人合富（中国） 医疗科技股份有限公司董事会提名为合富（中国）医疗科技 股份有限公司第三届董事会独立董事候选人。本人公开声明， 本人具备独立董事任职资格，保证不存在任何影响本人担任 合富（中国）医疗科技股份有限公司独立董事独立性的关系， 具体声明并承诺如下： 一、本人具备上市公司运作的基本知识，熟悉相关法 律、行政法规、部门规章及其他规范性文件，具有 5 年以上法 律、经济、会计、财务、管理或者其他履行独立董事职责所必需 的工作经验。 被提名人已经参加培训并取得证券交易所认可的相关培 训证明材料（如有） 二、本人任职资格符合下列法律、行政法规和部门规章 以及公司规章的要求： （一） 《中华人民共和国公司法》关于董事任职资格的规 定； （二）中国证监会《上市公司独立董事管理办法》、上海 证券交易所自律监管规则以及公司章程有关独立董事任职资 格和条件的相关规定； （三）其他法律法规、部门规章、规范性文件和上海证 券交易所规定的情形。 三、本人具备独立性，不属于下列情形： （四）在上市公司控股股东、实际控制人的附属企业任 职的人员及其配偶、父母、子女； ...

证券代码：603122 证券简称：合富中国 公告编号：临 2025-021 合富（中国）医疗科技股份有限公司 关于董事会换届选举的公告 本公司董事会及除独立董事 Stanley Yi Chang 先生以外的董事保证本公告 内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准 确性和完整性承担法律责任。 合富（中国）医疗科技股份有限公司（以下简称"公司"）第二届董事会于 （以下简称"《公司 法》"）、 《上海证券交易所股票上市规则》等法律、法规以及《合富（中国）医疗 科技股份有限公司章程》 为保证公司董事会的正常运作，在 2024 年年度股东大会审议通过前述事项 前，仍由第二届董事会按照《公司法》和《公司章程》等相关规定履行职责。 特此公告。 合富（中国）医疗科技股份有限公司董事会 附件：董事候选人简历 科学历。1983 年 11 月至 1996 年 4 月，任职于美国贝克曼仪器有限公司，担任 大中华区总经理；1996 年 5 月至 1996 年 9 月，任职于荷商飞利浦公司医疗部门， 担任大中华区总经理；1997 年 7 月至 2019 年 6 月担任合富生化科技股份有限公 司执行长；200 ...

Company Overview - Madi Technology closed at 15.44 yuan, up 2.93%, with a latest price-to-book ratio of 5.75 and a total market capitalization of 4.729 billion yuan [1] - As of the first quarter of 2025, there is one institutional holder of Madi Technology, holding a total of 49.2201 million shares valued at 0.637 billion yuan [1] Business Operations - Suzhou Madi Technology Co., Ltd. specializes in providing Clinical Information System (CIS) application software and overall solutions for clinical information management [1] - The company's main products include self-developed software, comprehensive solutions, purchased software and hardware, operational and technical services, medical service income, and photovoltaic battery cells [1] Financial Performance - For the first quarter of 2025, Madi Technology reported operating revenue of 63.34 million yuan, a year-on-year decrease of 43.13% [1] - The net profit for the same period was 23.5959 million yuan, showing a year-on-year increase of 138.55% [1] - The sales gross margin stood at 66.10% [1] Industry Comparison - Madi Technology's price-to-earnings (P/E) ratio (TTM) is -17.79, while the industry average is 113.36 [2] - The industry median P/E ratio is 20.17, indicating that Madi Technology's valuation is significantly lower than the industry average [2] - The total market capitalization of Madi Technology is 4.729 billion yuan, compared to the industry average of 11.359 billion yuan [2]

证券代码：688273 证券简称：麦澜德 公告编号：2025-019 南京麦澜德医疗科技股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 回购方案首次披露日 2024/7/2，由控股股东杨瑞嘉先生和史志怀先生提议 回购方案实施期限 2024 年 7 月 1 日~2025 年 6 月 30 日 预计回购金额 2,000万元~4,000万元 回购价格上限 31.61元/股 □减少注册资本 √用于员工持股计划或股权激励 回购用途 | □用于转换公司可转债 | | | --- | --- | | □为维护公司价值及股东权益 | | | 实际回购股数 | 108.21万股 | | 实际回购股数占总股本比例 | 1.08% | | 实际回购金额 | 2,135.1187万元 | | 实际回购价格区间 | 18.57元/股~26.00元/股 | | 一、回购审批情况和回购方案内容 | | 股股东杨瑞嘉先生和史志怀先生向公司董事会提议公司以自有资金通过集中竞价 交易方式实施股份回购。2024 年 7 月 1 日 ...

Group 1 - The core viewpoint of the news is that Yangpu Medical's stock has experienced a decline, with a closing price of 6.51 yuan, marking a 2.36% increase, but the latest price-to-book ratio is at a new low of 3.28 in 106 days, with a total market value of 2.013 billion yuan [1] - The company has seen a net outflow of main funds amounting to 4.2583 million yuan on June 3, and a total outflow of 9.6235 million yuan over the past five days, indicating a trend of capital withdrawal [1] - Yangpu Medical specializes in precision medicine, smart healthcare, and testing services, with its main product being a specimen management system [1] Group 2 - The latest financial performance report for the first quarter of 2025 shows that the company achieved an operating income of 116 million yuan, a year-on-year decrease of 18.15%, while net profit reached 7.8084 million yuan, reflecting a year-on-year increase of 344.71%, with a gross profit margin of 40.19% [1] - In comparison to industry averages, Yangpu Medical's price-to-earnings ratio (TTM) is -18.83, and its price-to-book ratio is 3.28, while the industry average P/E ratio is 50.80 [2] - The total market value of Yangpu Medical is reported at 2.013 billion yuan, which is significantly lower than the industry median of 5.019 billion yuan [2]

Group 1 - The development of AI in Shanghai is enhancing disease diagnosis and treatment, serving as a valuable assistant for clinicians and a tool for health education in schools, communities, and families [1][2] - The AI model "Qizhi," focused on children's brain health, has been launched in Shanghai, enabling rapid identification of brain abnormalities through patient-uploaded reports, thus improving diagnostic capabilities for grassroots doctors [1] - The "CardioMind" model, introduced at the 19th Oriental Cardiology Conference, showcases advanced multimodal data integration and deep reasoning capabilities, significantly improving diagnostic accuracy and reducing misdiagnosis [1] Group 2 - The establishment of the "Tumor-Cardiology AI Consortium" aims to address the challenges of treating immune myocarditis in cancer patients by integrating various myocardial injury markers and new indicators developed by a multidisciplinary team [2] - AI is expected to optimize medical resource allocation and enhance accessibility to healthcare services, extending its applications beyond hospitals to schools, communities, and homes [2] - The "Smart Eye Spirit," an AI eye health assistant, debuted during a children's eye health event, providing immediate answers to public inquiries about eye care [2] Group 3 - The accuracy and reliability of large models depend on the quality of training data, and challenges such as patient trust in digital doctors and compliance with ethical and regulatory standards must be addressed for AI's effective application in medicine [3]

Group 1 - The 20th China Western International Expo showcased over 3,000 enterprises, signing 416 investment cooperation projects with a total investment amount of 354.3 billion yuan, highlighting the investment potential of Western China [1] - The expo served as a platform for Western regions to demonstrate achievements in technology innovation, industrial upgrading, and foreign trade expansion, with Qinghai province presenting over 20 quality enterprises to enhance market influence [2] - Chengdu's exhibition focused on breakthroughs in artificial intelligence, aerospace, and digital cultural creativity, with companies like WoFei ChangKong establishing their global headquarters in Chengdu and planning to create an industrial park [3] Group 2 - The expo emphasized regional cooperation, featuring guest provinces and countries, and showcased successful collaborations in fields like artificial intelligence and new energy [4] - Zhejiang province highlighted its cooperation with Western regions, including a 23 billion yuan investment in a new materials industry base in Sichuan [4] - The Chengdu-Chongqing economic circle is accelerating development, with plans to promote 200 selected investment projects totaling over 1.1 trillion yuan at the upcoming investment promotion conference [4] Group 3 - The expo attracted enterprises from 62 countries and regions, with significant participation from Southeast Asia, the Middle East, Africa, and Latin America, marking a new high in internationalization [6] - The previous 19 expos have cumulatively attracted over 100 countries and regions, 68,000 enterprises, and 580,000 participants, establishing the expo as a high-level open platform for cooperation [6]

Core Insights - The 19th Oriental Cardiovascular Conference (OCC2025) in Shanghai introduced the "CardioMind" model, which excels in multimodal data integration, deep reasoning, and diagnosing complex rare diseases [1][3][6] - The model demonstrated its capabilities through a simulated consultation, accurately diagnosing hereditary hemorrhagic telangiectasia type II, a rare clinical condition [3][6] Group 1: Model Features and Capabilities - "CardioMind" utilizes a general base model trained on extensive medical data, including guidelines and clinical trials, enabling a fully automated process from history collection to diagnostic assistance [6] - The model's "slow thinking" and deep reasoning mechanisms aim to reduce misdiagnoses caused by incomplete information, enhancing diagnostic accuracy [6] - Continuous learning and updates are integral to the model, ensuring it remains current with medical advancements [6] Group 2: Expert Insights and Applications - Experts highlighted the potential of artificial intelligence (AI) to optimize healthcare resource allocation and improve accessibility to medical services [6] - The accuracy and reliability of large models depend on the quality of training data, and challenges such as patient trust in digital doctors and compliance with ethical and regulatory standards must be addressed [6] - The conference emphasized the integration of big data, AI, and digital therapies into academic exchanges, reflecting a commitment to high-quality development in cardiovascular disease prevention and treatment [6] Group 3: AI in Clinical Practice - Demonstrations of AI in complex coronary interventions showcased its ability to integrate various imaging data, enhancing precision in procedures for patients with chronic total occlusions [9] - AI is expected to significantly expand physicians' knowledge bases, improve clinical skills, and accelerate the learning curve from junior to senior doctors [9] - The role of AI extends beyond data analysis to include target discovery, small molecule compound design, and optimization of clinical trials, marking it as an indispensable tool for current and future researchers [10]